Synovus Financial Corp grew its holdings in Shire PLC (NASDAQ:SHPG) by 0.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,780 shares of the biopharmaceutical company’s stock after purchasing an additional 11 shares during the period. Synovus Financial Corp’s holdings in Shire PLC were worth $458,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also added to or reduced their stakes in SHPG. Hartford Financial Management Inc. increased its stake in shares of Shire PLC by 5.4% in the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $102,000 after acquiring an additional 32 shares during the last quarter. Thompson Davis & CO. Inc. grew its position in shares of Shire PLC by 3.1% in the first quarter. Thompson Davis & CO. Inc. now owns 640 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 19 shares during the last quarter. Pacer Advisors Inc. acquired a new stake in shares of Shire PLC in the second quarter valued at about $171,000. Stephens Inc. AR acquired a new stake in shares of Shire PLC in the first quarter valued at about $179,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Shire PLC in the first quarter valued at about $182,000. Institutional investors own 19.13% of the company’s stock.
Shire PLC (NASDAQ SHPG) opened at 157.86 on Friday. The stock’s 50 day moving average is $153.73 and its 200-day moving average is $168.99. Shire PLC has a 12 month low of $139.36 and a 12 month high of $209.22. The company has a market capitalization of $47.02 billion, a PE ratio of 70.63 and a beta of 1.61.
Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.37 EPS for the quarter, missing the Zacks’ consensus estimate of $3.66 by ($0.29). Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. On average, analysts expect that Shire PLC will post $14.93 EPS for the current year.
The company also recently declared a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be issued a dividend of $0.1527 per share. The ex-dividend date of this dividend is Thursday, September 7th. This represents a yield of 0.21%. Shire PLC’s dividend payout ratio is currently 41.07%.
SHPG has been the topic of several research analyst reports. Royal Bank Of Canada set a $221.00 price target on Shire PLC and gave the company a “buy” rating in a research report on Thursday, May 18th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $210.00 target price on shares of Shire PLC in a research note on Thursday, July 13th. HSBC Holdings plc upgraded shares of Shire PLC from a “reduce” rating to a “hold” rating in a research note on Thursday, July 6th. Jefferies Group LLC restated a “buy” rating and set a $216.00 price target (down previously from $239.00) on shares of Shire PLC in a research note on Friday, June 9th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $222.00 price target on shares of Shire PLC in a research note on Monday, August 21st. One research analyst has rated the stock with a sell rating, ten have given a hold rating and fourteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $220.08.
Shire PLC Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with our FREE daily email newsletter.